BSMA’s COMMITMENT TO COMMERCIALIZE CELL & GENE THERAPY

The innovative therapy of Cell and Gene Therapy has imposed Draconian demands on the supply chain of the embryonic industry in terms of production batch of one, sixteen day vein to vein lead time, cryogenic preservation and cold-chain logistics, chain of custody,...